Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance).


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Nixon, AB; Sibley, A; Hatch, AJ; Liu, Y; Jiang, C; Mulkey, F; Starr, MD; Brady, JC; Niedzwiecki, D; Innocenti, F; Venook, AP; Hochster, HS; Lenz, H-J; O'Neil, BH; Owzar, K; Hurwitz, H

Published Date

  • May 20, 2016

Published In

Volume / Issue

  • 34 / 15_suppl

Start / End Page

  • 3597 - 3597

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2016.34.15_suppl.3597